Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Julie Irving

Newcastle AuthorsTitleYearFull text
Erhan Aptullahoglu
Mohammed Howladar
Dr Jonathan Wallis
Dr Helen Marr
Professor Julie Irving
et al.		Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia2025
Dr Hayden Bell
Dr Helen Blair
Samantha Jepson Gosling
Dr Martin Galler
Dan Astley
et al.		Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia2024
Dr Dino Masic
Dr Hayden Bell
Dr Frederik van Delft
Professor Julie Irving
Selection of dormant cells during treatment of T-lineage lymphoblastic leukemia and CREB as a therapeutic target2024
Dr Jill Hunter
Dr Elaine Willmore
Professor Julie Irving
Dr Stephany Veuger
Correction to: NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699 (Oncogene, (2012), 31, 2, (251-264), 10.1038/onc.2011.229)2023
Dr Richard Gallon
Rachel Phelps
Christine Hayes
Dr Dino Masic
Professor Julie Irving
et al.		Detection of constitutional mismatch repair deficiency in children and adolescents with acute lymphoblastic leukemia2023
Dr Dino Masic
Kayleigh Fee
Dr Hayden Bell
Marian Case
Juan Ojeda Garcia
et al.		Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia2023
Dr Hayden Bell
Dr Helen Blair
Mankaran Singh
Professor Anthony Moorman
Professor Olaf Heidenreich
et al.		Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia2023
Professor Julie Irving
Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature2022
Dr Tobias Menne
Professor Julie Irving
Professor Ruth Plummer
Dr Geoff Shenton
Professor Gareth Veal
et al.		Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial2022
Professor Anthony Moorman
Professor Julie Irving
Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials2021
Dr Amir Enshaei
Dr Sirintra Nakjang
Lynne Minto
Professor Julie Irving
Beth Poole
et al.		The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia2021
Marian Case
Dr Dino Masic
Dr David Jamieson
Dr Frederik van Delft
Professor Andrew Filby
et al.		Label-Free Leukemia Monitoring by Computer Vision2020
Liz Matheson
Huw Thomas
Marian Case
Dr Helen Blair
Rosanna Jackson
et al.		Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM2019
Dr Rosanna Jackson
Philip Berry
Julie Errington
Professor Julie Irving
Professor Gareth Veal
Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia - a report from the UKALL 2011 trial2019
Dr Lina Hamadeh
Professor Julie Irving
Professor Anthony Moorman
Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial2019
12345678910